Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, announced that Tai Tien Pharmaceuticals Co., which is a consolidated subsidiary of MTPC, has entered into a sub-license agreement with Kissei Pharmaceutical Co., Ltd. to license development and commercialization rights in Taiwan for fostamatinib disodium hexahydrate, a spleen tyrosine kinase (SYK) inhibitor.

This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion, thereby improving the bleeding symptoms caused by chronic idiopathic thrombocytopenic purpura (ITP).

By executing this agreement, Tai Tien will gain the rights to develop and commercialize this product in Taiwan and will pay Kissei an upfront payment and milestones based on the progress of commercialization. Kissei will supply the formulation to Tai Tien.

More than 60 years, based on the pharmaceutical development and sales foundation in Taiwan, MTPC has been focusing on cardiovascular diseases and metabolism, as well as autoimmune diseases. Through our own products and partnerships with other companies, MTPC contributes to patients by delivering a wide range of treatments in Taiwan.